# A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

> **NCT02720263** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ASP4345
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT02720263
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-28
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-06-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720263, "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02720263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*